Daraxonrasib Phase 3 RASolute 302 positive results
KEY STEPOn April 13, 2026, Revolution Medicines reported positive Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic cancer. The result triggered a $250 million Royalty Pharma funding tranche and increased its tiered royalty rights.
Roadmap reference